Skip to Content

Does Mavyret cure hep C (HCV)? What is the success rate?

Medically reviewed by Melisa Puckey, BPharm. Last updated on July 22, 2020.

Official Answer

by Drugs.com

Does Mavyret cure hepatitis C (HCV)? What is the success rate?

Yes, Mavyret is a treatment that can clinically cure hepatitis C viral infection (HCV).
The success rate for curing hepatitis C with Mavyret ranges from 95 to 99%.

How successful Mavyret (glecaprevir and pibrentasvir) is at treating hepatitis C depends on the:

  • form (or genotype) of hepatitis C
  • if you have cirrhosis of the liver, and at what stage your cirrhosis is
  • if you have already have or have not had treatment for hepatitis C
  • If you have HIV as well as hepatitis C

Hepatitis C has 6 different forms (or genotypes) and each different form has a different success rate when treated with Mavyret.
Liver cirrhosis seems to make it harder to clear the hepatitis infection so if you have cirrhosis you may need to have a longer treatment of 12 weeks.

Clinical Trials of Mavyret


In the Mavyret clinical trials hepatitis C is considered to be clinically cured when the blood test measuring hepatitis C viral RNA comes back as less than 15 IU/mL. This blood test is done 12 weeks after finishing treatment. It is regarded that hepatitis C has relapsed when the blood test level of hepatitis C RNA is over 15IU/mL.
The results below are from clinical trials that included patients who had never had hepatitis C treatment and patients who had already tried hepatitis C treatments.

Success rate of Mavyret for hepatitis C: Table.

Patients without cirrhosis Patients with cirrhosis Patients with cirrhosis
Genotype Mavyret 8 week treatment Mavyret 8 week treatment Mavyret 12 week treatment
GT1 99% (348/351) 98% (226/231) 99% (89/90)
GT2 98% (193/197) 98% (26/26) 100% (31/31)
GT4 93% (43/46) 100% (13/13) 100% (16/16)
GT5 95% (21/22) 100% (1/1) 100% (5/5)
GT6 100% (65/65) 100% (9/9) 92% (12/13)


Genotype 3 is harder to clear than the other genotypes of hepatitis C. The clinical trials for genotype 3 used only patients who had previously not had any hepatitis C treatments, which you would expect to have a better response compared to other clinical trials that included both patients who had and had not had previous treatment. The patients in the genotype 3 trial also had no cirrhosis. The results for treatment for 8 week with Mavyret were 95% (149/157) and for the 12 week treatment was 95% (222/233).

Bottom Line:

  • Mavyret is an 8 to 12 week treatment for hepatitis C infection.
  • Mavyret success rate for curing hepatitis C is between 95 to 99%.
  • The success of Mavyret to cure hepatitis C is dependent on a number of factors including genotype of hepatitis C, whether or not you have cirrhosis, previous hepatitis C treatments and other medical conditions you may have.
References

Related Medical Questions

Drug Information

Related Support Groups